Literature DB >> 33824467

Evaluating the monogenic contribution and genotype-phenotype correlation in patients with isolated thoracic aortic aneurysm.

Yang Li1,2,3, Yu Kong1,2,3, Weixun Duan4, Shiqiang Yu4, Xinmin Zhou5, Yerong Hu5, Jing-Song Ou6, Dinghua Yi4, Jinsheng Xie1,2, Junming Zhu1,2, Lizhong Sun1,2, Yulin Li7,8,9, Jie Du10,11,12.   

Abstract

Thoracic aortic aneurysm with or without dissection (TAAD) can be broadly categorized as syndromic TAAD (sTAAD) and isolated TAAD (iTAAD). sTAAD and is highly correlated with genetics. However, although the incidence of iTAAD is much higher, its monogenic contribution is not yet clear. Here, we sequenced 15 known TAAD genes for 578 iTAAD cases from four cardiac centers in China and found that 10.6% patients with a pathogenic/likely pathogenic (P/LP) variant. Other 7.27% of patients carried variants of uncertain significance in these target genes. We further investigated the correlations among genetics, clinical features, and long-term outcomes. Genetic patients showed younger onset ages (P = 1.31E-13) and larger aortic diameter (P = 1.00E-6), with the youngest age in patients with FBN1 P/LP variants. Monogenic variants were also associated with more aortic segments involved (P = 0.043) and complicated with initial dissection (P = 4.50E-5), especially for genetic patients with non-FBN1 P/LP variants. MACEs occurred in 14.9% patients during follow-up of median 55 months. Genetic status (P = 0.001) and initial dissection (P = 3.00E-6) were two major risk factors for poor prognosis. Early onset age was associated with MACEs in non-genetic cases without initial dissection (P = 0.005). Our study revealed the monogenic contribution in known TAAD genes to iTAAD patients. The genotype-phenotype correlations may complement the risk stratification of iTAAD patients and identification of higher risk subgroups, as well as assist the development of tailored precision medicine in iTAAD.
© 2021. The Author(s), under exclusive licence to European Society of Human Genetics.

Entities:  

Mesh:

Year:  2021        PMID: 33824467      PMCID: PMC8298584          DOI: 10.1038/s41431-021-00857-2

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   5.351


  32 in total

1.  Loss of function mutation in LOX causes thoracic aortic aneurysm and dissection in humans.

Authors:  Vivian S Lee; Carmen M Halabi; Erin P Hoffman; Nikkola Carmichael; Ignaty Leshchiner; Christine G Lian; Andrew J Bierhals; Dana Vuzman; Robert P Mecham; Natasha Y Frank; Nathan O Stitziel
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

2.  M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity.

Authors:  Karthik A Jagadeesh; Aaron M Wenger; Mark J Berger; Harendra Guturu; Peter D Stenson; David N Cooper; Jonathan A Bernstein; Gill Bejerano
Journal:  Nat Genet       Date:  2016-10-24       Impact factor: 38.330

Review 3.  Cellular Mechanisms of Aortic Aneurysm Formation.

Authors:  Raymundo Alain Quintana; W Robert Taylor
Journal:  Circ Res       Date:  2019-02-15       Impact factor: 17.367

Review 4.  Expert consensus recommendations on the cardiogenetic care for patients with thoracic aortic disease and their first-degree relatives.

Authors:  Judith M A Verhagen; Marlies Kempers; Luc Cozijnsen; Berto J Bouma; Anthonie L Duijnhouwer; Jan G Post; Yvonne Hilhorst-Hofstee; Sebastiaan C A M Bekkers; Wilhelmina S Kerstjens-Frederikse; Thomas J van Brakel; Eric Lambermon; Marja W Wessels; Bart L Loeys; Jolien W Roos-Hesselink; Ingrid M B H van de Laar
Journal:  Int J Cardiol       Date:  2018-02-07       Impact factor: 4.164

5.  Genome-wide association study identifies a susceptibility locus for thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21.1.

Authors:  Scott A LeMaire; Merry-Lynn N McDonald; Dong-Chuan Guo; Ludivine Russell; Charles C Miller; Ralph J Johnson; Mir Reza Bekheirnia; Luis M Franco; Mary Nguyen; Reed E Pyeritz; Joseph E Bavaria; Richard Devereux; Cheryl Maslen; Kathryn W Holmes; Kim Eagle; Simon C Body; Christine Seidman; J G Seidman; Eric M Isselbacher; Molly Bray; Joseph S Coselli; Anthony L Estrera; Hazim J Safi; John W Belmont; Suzanne M Leal; Dianna M Milewicz
Journal:  Nat Genet       Date:  2011-09-11       Impact factor: 38.330

Review 6.  Heritable thoracic aortic disorders.

Authors:  Reed E Pyeritz
Journal:  Curr Opin Cardiol       Date:  2014-01       Impact factor: 2.161

7.  Importance of the clinical recognition of Loeys-Dietz syndrome in the neonatal period.

Authors:  Anji T Yetman; Rebecca S Beroukhim; Dunbar D Ivy; David Manchester
Journal:  Pediatrics       Date:  2007-05       Impact factor: 7.124

8.  Reference values for echocardiographic assessment of the diameter of the aortic root and ascending aorta spanning all age categories.

Authors:  Laurence Campens; Laurent Demulier; Katya De Groote; Kristof Vandekerckhove; Daniël De Wolf; Mary J Roman; Richard B Devereux; Anne De Paepe; Julie De Backer
Journal:  Am J Cardiol       Date:  2014-07-03       Impact factor: 2.778

Review 9.  Managing Thoracic Aortic Aneurysm in Patients with Bicuspid Aortic Valve Based on Aortic Root-Involvement.

Authors:  Elizabeth Norton; Bo Yang
Journal:  Front Physiol       Date:  2017-06-13       Impact factor: 4.566

10.  Aortic disease in the young: genetic aneurysm syndromes, connective tissue disorders, and familial aortic aneurysms and dissections.

Authors:  Marcelo Cury; Fernanda Zeidan; Armando C Lobato
Journal:  Int J Vasc Med       Date:  2013-01-14
View more
  1 in total

1.  A +3 variant at a donor splice site leads to a skipping of the MYH11 exon 32, a recurrent RNA defect causing Heritable Thoracic Aortic Aneurysm and Dissection and/or Patent Ductus Arteriosus.

Authors:  Bertrand Chesneau; Aurélie Plancke; Guillaume Rolland; Bertrand Marcheix; Yves Dulac; Thomas Edouard; Julie Plaisancié; Marion Aubert-Mucca; Sophie Julia; Maud Langeois; Thierry Lavabre-Bertrand; Philippe Khau Van Kien
Journal:  Mol Genet Genomic Med       Date:  2021-10-21       Impact factor: 2.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.